ALLO
insider transactionsAllogene Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-12.5K
0 buy · 12.5K sell
Net value · 90d
-$29.3K
$0 in · $29.3K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
2
0 buy · 12.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
SVP, Finance
$22.1K
9.6K sh · $2.31
Own -7%
-
Sell·S
SVP, Chief Technical Officer
$7.2K
2.9K sh · $2.50
Own -1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 21, 2026 | Annie Yoshiyama | Sell S | 9.6K | $22.1K |
| Mar 31, 2026 | Benjamin Machinas Beneski | Sell S | 2.9K | $7.2K |
About ALLO insider trading
This page tracks insider transactions for Allogene Therapeutics, Inc. (ALLO) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.